Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

RPS chief executive to step down next year

The Royal Pharmaceutical Society’s (RPS) chief executive Helen Gordon will leave the organisation next year, it has announced.

The RPS is now “underway” with a recruitment process to replace her, it said today (November 17).

Ms Gordon, who joined the RPS as CEO in 2010, is leaving to take up the chief executive position at the Royal Society of Medicine.

During her time at the RPS, Ms Gordon helped introduce its faculty programme and increased the international “profile and contribution” of the organisation, the RPS said.

In a statement, Ms Gordon paid credit to the RPS, which she branded a “thriving professional body [that] will continue to go from strength to strength”.

RPS president Martin Astbury stressed that much of the organisation’s success is due to Ms Gordon’s “leadership and drive” as CEO. “We are now a more influential organisation, with a higher profile and growing membership,” he said.

Who would you like to be named the next RPS CEO?

Related Content

Topics



Pharmacist Managers - Recruiting Now !
East London, Essex and Luton
£40,000 - £50,000 per year

Apply Now
UsernamePublicRestriction

Register

CD008447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel